Department of Hematology,920th Hospital of Joint Logistics Support Force
Kunming, Yunnan, 650000, China
NCT Number: NCT06837987
The investigators retrospectively evaluted the safety and efficacy of the modified transplantation conditioning and aGVHD prophylaxis in severe aplastic anemia in 4 transplantation centers.
Looking for future studies?
Notify Me3 year–65 year
All sexes
Observational
Kunming, Yunnan, 650000, China
Aplastic anemia (AA) is a group of myelo-hemopoietic failure syndromes caused by a variety of etiologies. If not intervened, the average expected survival time is less than half a year.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the possible cures for this disease. The success rate of treatment for this disease can be further improved under the previous regimen system. The survival rate reported in the literature is 60%-90%. From Jun. 2020 to Dec. 2023, 72 patients in 4 transplantation center received this modified transplantation system, The investigators designed this clinical trial to retrospectively evaluted the safety and efficacy of the modified transplantation conditioning and aGVHD prophylaxis in severe aplastic anemia in the 4 clinical center.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Modified transplantation conditioning include: Fludarabine 30mg/m2*6 day, Melphalan 100mg/m2*1 day, cyclophosphamide 50mg/kg*2 day.
Time frame: From the day of HSCs transfusion to +100 day after HSCT.
no apperance or complete loss of donor-derived neutrophils by +28 days
Time frame: From the day of HSCT transfusion to 100 days after HSCT
proportion of patients who developed aGVHD within 100 days after HSCT
Time frame: From the day of HSCs transfusion to 24 months after HSCT
the presence of at least two cytopenic counts beyond +28 days with a transfusion requirement associated with hypoplastic-aplastic bone marrow
Time frame: From +100 days after HSCT to the follow-up date
the proportion of patients who developed chronic GVHD within the observation duration
Time frame: From the first day of preconditioning to +100 days after hematopoietic stem cell Transfusion
the incidence of adverse events during the transplantation preconditioning periods.
Time frame: 24 months
proportioin of patients who still be alive within 24 months after HSCT
Time frame: 24 months
proportion of patients still be alive without GVHD or other diseases.
Hematology department of the 920th hospital
Other
An Observation of the Safety and Efficacy of a Modified Transplantation Conditioning and aGVHD Prophylaxis for Severe Aplastic Anemia--a Retrospective, Double-center, Single-arm Clinical Study.
Acronym: aGVHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01933035
Anemia, Anemia, Aplastic
New York, United States
View Trial DetailsNCT07586735
Anemia, Anemia, Aplastic
Beijing, Beijing Municipality, China
View Trial DetailsNCT07499284
Anemia, Anemia, Aplastic
Suzhou, Jiangsu, China
View Trial DetailsNCT07461116
Anemia, Anemia, Aplastic
Tianjin, China
View Trial Details